On Tuesday, Editas Medicine Inc (NASDAQ: EDIT) opened higher 3.42% from the last session, before settling in for the closing price of $3.8. Price fluctuations for EDIT have ranged from $0.91 to $4.07 over the past 52 weeks.
A company in the Healthcare sector has dropped its sales by -1.48% annually for the last half of the decade. Company’s average yearly earnings per share was noted 29.37% at the time writing. With a float of $89.11 million, this company’s outstanding shares have now reached $89.92 million.
Editas Medicine Inc (EDIT) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Editas Medicine Inc is 0.90%, while institutional ownership is 47.44%. The most recent insider transaction that took place on Sep 03 ’25, was worth 1,843. In this transaction EVP, CHIEF SCIENTIFIC OFFICER of this company sold 710 shares at a rate of $2.60, taking the stock ownership to the 69,490 shares. Before that another transaction happened on Sep 03 ’25, when Company’s SVP, Chief Financial Officer sold 458 for $2.60, making the entire transaction worth $1,189. This insider now owns 16,369 shares in total.
Editas Medicine Inc (EDIT) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.75 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.77) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.49% during the next five years compared to -1.48% drop over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Check out the current performance indicators for Editas Medicine Inc (EDIT). In the past quarter, the stock posted a quick ratio of 2.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.85, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -1.09 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Let’s dig in a bit further. During the last 5-days, its volume was 3.44 million. That was better than the volume of 2.81 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 83.17%.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 94.86%, which indicates a significant increase from 90.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.30 in the past 14 days, which was higher than the 0.24 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.85, while its 200-day Moving Average is $1.99. However, in the short run, Editas Medicine Inc’s stock first resistance to watch stands at $4.06. Second resistance stands at $4.18. The third major resistance level sits at $4.37. If the price goes on to break the first support level at $3.74, it is likely to go to the next support level at $3.55. Assuming the price breaks the second support level, the third support level stands at $3.43.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
There are currently 89,920K shares outstanding in the company with a market cap of 353.39 million. Presently, the company’s annual sales total 32,310 K according to its annual income of -237,090 K. Last quarter, the company’s sales amounted to 3,580 K and its income totaled -53,240 K.
